The overall goal of this renewal application is to understand how myristoylated retroviral proteins are trafficked through the cell, targeted to the plasma membrane and assembled into virions. This will be accomplished by studying the HIV-1 Gag polyprotein, Pr55gag. Use of HIV-1 as a model system is dually advantageous. First, these studies allow us to address key basic questions regarding membrane targeting of myristoylated proteins. Second, elucidation of the molecular mechanisms involved in Gag membrane association and multi-merization will provide new insights into the process of HIV infection and will serve to define novel targets for drug development that could interfere with formation of HIV-1 virions and be efficacious for the treatment of AIDS. Specifically, the proposed research will address the following issues: 1. Identification of assembly site domains in the plasma membrane Pulse/chase labeling combined with density gradient centrifugation will be used to molecularly define discrete steps of viral particle assembly at the plasma membrane. Gradient fractions containing Gag will be isolated and characterized in order to establish a temporal order to the assembly process. 2. When and where does oligomerization of Pr55gag occur? Gag multi-merization constitutes a critical step in virus assembly, yet it is not known when and where Gag-Gag interactions occur in the cell. We will determine the multi-merization state of Pr55gag at different stages during its biosynthetic trafficking and correlate the degree of multi-merization with specific assembly intermediates. 3. Visualization of Gag trafficking and assembly in live cells. Pr55gag will be fused to different color variants of GFP in order to monitor membrane localization and Gag-Gag interactions by real time confocal microscopy. These experiments will complement the biochemical studies in Aims 1 and 2 and are likely to provide a fascinating view of Gag movement and dynamics in live cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA072309-04A1
Application #
6148334
Study Section
Special Emphasis Panel (ZRG1-AARR-1 (01))
Program Officer
Read-Connole, Elizabeth Lee
Project Start
1996-07-15
Project End
2004-01-31
Budget Start
2000-02-02
Budget End
2001-01-31
Support Year
4
Fiscal Year
2000
Total Cost
$255,623
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Resh, Marilyn D (2012) Targeting protein lipidation in disease. Trends Mol Med 18:206-14
Rai, Tia; Mosoian, Arevik; Resh, Marilyn D (2010) Annexin 2 is not required for human immunodeficiency virus type 1 particle production but plays a cell type-dependent role in regulating infectivity. J Virol 84:9783-92
Martinez, Nathaniel W; Xue, Xiaoxiao; Berro, Reem G et al. (2008) Kinesin KIF4 regulates intracellular trafficking and stability of the human immunodeficiency virus type 1 Gag polyprotein. J Virol 82:9937-50
Valiathan, Rajeshwari R; Resh, Marilyn D (2008) Differential control of CXCR4 and CD4 downregulation by HIV-1 Gag. Virol J 5:23
Resh, Marilyn D (2006) Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol 2:584-90
Perlman, Mira; Resh, Marilyn D (2006) Identification of an intracellular trafficking and assembly pathway for HIV-1 gag. Traffic 7:731-45
Resh, Marilyn D (2006) Use of analogs and inhibitors to study the functional significance of protein palmitoylation. Methods 40:191-7
Resh, Marilyn D (2005) Intracellular trafficking of HIV-1 Gag: how Gag interacts with cell membranes and makes viral particles. AIDS Rev 7:84-91
Lindwasser, O Wolf; Resh, Marilyn D (2004) Human immunodeficiency virus type 1 Gag contains a dileucine-like motif that regulates association with multivesicular bodies. J Virol 78:6013-23
Valiathan, Rajeshwari R; Resh, Marilyn D (2004) Expression of human immunodeficiency virus type 1 gag modulates ligand-induced downregulation of EGF receptor. J Virol 78:12386-94

Showing the most recent 10 out of 20 publications